Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck
Status: Enrolling
Updated:  11/9/2017
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck
Status: Enrolling
Updated: 11/9/2017
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
PK Button Vaporization Electrode for Treatment of Bladder Tumors
Status: Enrolling
Updated:  11/9/2017
Emory University Department of Urology
mi
from
Atlanta, GA
PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors
PK Button Vaporization Electrode for Treatment of Bladder Tumors
Status: Enrolling
Updated: 11/9/2017
Emory University Department of Urology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Torrance, CA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Lexington, KY
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Boston, MA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Omaha, NE
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
New York, NY
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Portland, OR
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Investigational Site Number 4104
mi
from
Porto Alegre,
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Investigational Site Number 4104
mi
from
Porto Alegre,
Click here to add this to my saved trials
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated:  11/9/2017
Washington University
mi
from
Saint Louis, MO
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Enrolling
Updated: 11/9/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Ronald Reagan UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Sarah Cannon Research Institute at HealthONE
mi
from
Denver, CO
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Sarah Cannon Research Institute at HealthONE
mi
from
Denver, CO
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Columbia University Medical Center
mi
from
New York, NY
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Laura And Isaac Perlmutter Cancer Center
mi
from
New York, NY
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Laura And Isaac Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Weill-Cornell Medical College
mi
from
New York, NY
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Providence Portland Medical Center
mi
from
Portland, OR
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
START (South Texas Accelerated Research Therapeutics)
mi
from
San Antonio, TX
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
START (South Texas Accelerated Research Therapeutics)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Mayo Clinic
mi
from
Phoenix, AZ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Norwalk Hospital
mi
from
Norwalk, CT
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Georgetown University Medical Center
mi
from
Washington,
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
University of Chicago
mi
from
Chicago, IL
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Duke Cancer Institute
mi
from
Durham, NC
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Stanford University
mi
from
Stanford, CA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Indiana University
mi
from
Indianapolis, IN
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
University of Kansas Cancer Center
mi
from
Fairway, KA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
University of Kansas Cancer Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Barbara Ann Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Mount Sinai Hospital
mi
from
New York, NY
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Miriam Hospital
mi
from
Providence, RI
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Mary Crowley Cancer Research Center - Medical City
mi
from
Dallas, TX
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Mary Crowley Cancer Research Center - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Baylor College of Medicine
mi
from
Houston, TX
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/9/2017
Northwest Medical Specialties
mi
from
Tacoma, WA
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/9/2017
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials